Reversing metabolic reprogramming by CPT1 inhibition with etomoxir promotes cardiomyocyte proliferation and heart regeneration via DUSP1 ADP-ribosylation-mediated p38 MAPK phosphorylation.
- DOI
- 10.1016/j.apsb.2024.11.001
- Published
- 2025 Jan
- Container
- Acta pharmaceutica Sinica. B
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.apsb.2024.11.001,
title = {Reversing metabolic reprogramming by CPT1 inhibition with etomoxir promotes cardiomyocyte proliferation and heart regeneration via DUSP1 ADP-ribosylation-mediated p38 MAPK phosphorylation.},
author = {Tang L and Shi Y and Liao Q and Wang F and Wu H and Ren H and Wang X and Fu W and Shou J and Wang WE and Jose PA and Yang Y and Zeng C},
year = {2025},
journal = {Acta pharmaceutica Sinica. B},
doi = {10.1016/j.apsb.2024.11.001},
url = {https://doi.org/10.1016/j.apsb.2024.11.001}
}RIS
TY - JOUR TI - Reversing metabolic reprogramming by CPT1 inhibition with etomoxir promotes cardiomyocyte proliferation and heart regeneration via DUSP1 ADP-ribosylation-mediated p38 MAPK phosphorylation. AU - Tang L AU - Shi Y AU - Liao Q AU - Wang F AU - Wu H AU - Ren H AU - Wang X AU - Fu W AU - Shou J AU - Wang WE AU - Jose PA AU - Yang Y AU - Zeng C PY - 2025 JO - Acta pharmaceutica Sinica. B DO - 10.1016/j.apsb.2024.11.001 UR - https://doi.org/10.1016/j.apsb.2024.11.001 ER -
APA
L, T., Y, S., Q, L., F, W., H, W., H, R., X, W., W, F., J, S., WE, W., PA, J., Y, Y., & C, Z. (2025). Reversing metabolic reprogramming by CPT1 inhibition with etomoxir promotes cardiomyocyte proliferation and heart regeneration via DUSP1 ADP-ribosylation-mediated p38 MAPK phosphorylation.. Acta pharmaceutica Sinica. B. https://doi.org/10.1016/j.apsb.2024.11.001
Source records
- pubmed · retrieved 2026-09-26T01:16:28.075Z
- europe-pmc · retrieved 2026-09-26T01:16:28.090Z